Law360 ( August 10, 2009, 2:30 PM EDT) -- On April 3, 2009, the Federal Circuit issued its decision in Ariad Pharmaceuticals Inc. v. Eli Lilly & Co., 560 F.3d 1366 (Fed. Cir. 2009), in which the court held, inter alia, that claims directed to a method of reducing Nuclear Factor Kappa B ("NF-kB") activity in cells were invalid for failing to satisfy the written description requirement under 35 U.S.C. § 112, paragraph 1....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.